Mitigare® (colchicine) and its authorized generic colchicine 0.6 mg capsules represent affordable options for gout flare prevention in appropriate adult patients.2-4 And with their blue pop of color, Mitigare® capsules are easy to identify from other prescribed daily medication.5

Mitigare® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare® for acute treatment of gout flares during prophylaxis has not been studied. Mitigare® is not an analgesic medication and should not be used to treat pain from other causes.

See Blue, Save Green

Use the True Blue Savings Card on Generic Colchicine 0.6 mg capsules or Mitigare® 0.6 mg capsules.

*Maximum savings of $65 on first fill, $50 on refills. Must meet eligibility requirements.
See Terms & Conditions and eligibility requirements.

DOWNLOAD YOUR CARD NOW

 

From the Gout Prevention Blog

Fast Facts on the Mitigare® (Colchicine) True Blue Savings Card

The Mitigare® True Blue Savings Card helps qualified patients save on their colchicine therapy. With the Mitigare® True Blue Savings Card, eligible patients can receive Mitigare® or the authorized generic (colchicine Read more...

color of a medication

From the Gout Prevention Blog

Why Is the Color of a Medication Important?

According to the US Food and Drug Administration, medication errors are the most common type of mistake made in health care.1 However, the color of a medication can reduce the Read more...

References

  1. Mitigare® (colchicine) capsules [prescribing information]. Eatontown, NJ; West-Ward Pharmaceutical Corp; 2015.
  2. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004 Dec;31(12):2429-2432.
  3. Yu et al. Efficacy of colchicine prophylaxis in gout. Prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects. Ann Intern Med. 1961;55:179-192.
  4. PriceRx for Wholesalers. Wolters Kluwer website. Available at http://www.wolterskluwercdi.com/wholesalers-pricerx/. Accessed October 1, 2016. 4. White Paper—What Is the Significance of the Color of a Pill. Wallcur, LLC. http://www.wallcur.com/whitepaper-pill-color.aspx. Accessed June 28, 2016.
  5. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. Oct 2011;63(10):3136-3141.
  6. Arthritis/Gout. Centers for Disease Control and Prevention website. Available at: http://www.cdc.gov/arthritis/basics/gout.html. Accessed November 30, 2016.

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.
  • Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported with colchicine used in therapeutic doses.
  • Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine.
  • Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death.
  • Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider temporary interruption or discontinuation of Mitigare®.
  • The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.

Indication

Mitigare® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare for acute treatment of gout flares during prophylaxis has not been studied.

Mitigare® is not an analgesic medication and should not be used to treat pain from other causes.

For Full Prescribing Information please CLICK HERE and for Medication Guide CLICK HERE.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Manufactured by: West-Ward Pharmaceuticals Corp., Eatontown, NJ 07724

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.